BE901186A - Procede et composition pour la preparation de produits pharmaceutiques a effet retard controle pour l'administration orale. - Google Patents

Procede et composition pour la preparation de produits pharmaceutiques a effet retard controle pour l'administration orale.

Info

Publication number
BE901186A
BE901186A BE0/214099A BE214099A BE901186A BE 901186 A BE901186 A BE 901186A BE 0/214099 A BE0/214099 A BE 0/214099A BE 214099 A BE214099 A BE 214099A BE 901186 A BE901186 A BE 901186A
Authority
BE
Belgium
Prior art keywords
preparation
composition
oral administration
pharmaceutical products
controlled delayed
Prior art date
Application number
BE0/214099A
Other languages
English (en)
Original Assignee
Lowey Hans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lowey Hans filed Critical Lowey Hans
Publication of BE901186A publication Critical patent/BE901186A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Une nouvelle composition pharmaceutique, comprend un véhicule pharmaceutique à libération prolongée convenant au mélange avec des principes actifs et renfermant : 9 5,5 à 98,5 % en poids d'hydroxypropyl méthylcellulose; b) 0,25 à 4,5 % en poids d'hydroxypropyl cellulose; c) 1 à 90 % en poids d'un polymère carboxyvinylique.
BE0/214099A 1983-12-01 1984-11-30 Procede et composition pour la preparation de produits pharmaceutiques a effet retard controle pour l'administration orale. BE901186A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/556,844 US4680323A (en) 1983-12-01 1983-12-01 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration

Publications (1)

Publication Number Publication Date
BE901186A true BE901186A (fr) 1985-03-15

Family

ID=24223083

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/214099A BE901186A (fr) 1983-12-01 1984-11-30 Procede et composition pour la preparation de produits pharmaceutiques a effet retard controle pour l'administration orale.

Country Status (26)

Country Link
US (1) US4680323A (fr)
JP (1) JPS60185728A (fr)
KR (1) KR930000046B1 (fr)
AT (1) AT394948B (fr)
AU (1) AU572571B2 (fr)
BE (1) BE901186A (fr)
CA (1) CA1229551A (fr)
CH (1) CH664970A5 (fr)
DE (1) DE3443587C2 (fr)
DK (1) DK162511C (fr)
EG (1) EG17134A (fr)
FI (1) FI82601C (fr)
FR (1) FR2555901B1 (fr)
GB (1) GB2152940B (fr)
HU (1) HU193717B (fr)
IE (1) IE58112B1 (fr)
IL (1) IL73594A (fr)
IT (1) IT1177152B (fr)
LU (1) LU85660A1 (fr)
MX (1) MX161165A (fr)
NL (1) NL193164C (fr)
NO (1) NO167002C (fr)
NZ (1) NZ210310A (fr)
PT (1) PT79427B (fr)
SE (1) SE461071B (fr)
ZA (1) ZA849373B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0153105B1 (fr) * 1984-02-10 1992-09-09 Benzon Pharma A/S Dose à base d'unités multiples enrobées par une couche de diffusion
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
EP0205336B1 (fr) * 1985-06-11 1991-09-11 Teijin Limited Préparation pharmaceutique orale à effet entretenn
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
US4783331A (en) * 1987-06-29 1988-11-08 Miles Inc. Method for solubilization of aspartame in effervescent aqueous systems; and composition
WO1989010745A1 (fr) * 1988-05-02 1989-11-16 Pomerantz, Edwin Compositions et procedes in situ pour la formation de pellicules sur des tissus du corps
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
EP0542926B1 (fr) * 1990-08-07 1995-02-15 Pfizer Inc. Emploi de membranes a polymerisation interfaciale dans des dispositifs de liberation
JP2626248B2 (ja) * 1991-04-08 1997-07-02 日本新薬株式会社 カプセル剤
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
ES2115638T3 (es) * 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
JP3707798B2 (ja) * 1996-05-13 2005-10-19 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 口内薬剤輸送系
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US6479082B1 (en) 1996-12-23 2002-11-12 Wm. Wrigley, Jr. Co. Process of increasing flavor release from chewing gum using hydroxypropyl cellulose and product thereof
CA2216215A1 (fr) 1997-04-05 1998-10-05 Isa Odidi Formulations a liberation prolongee, utilisant des polymeres intelligents, avec caracteristiques de mouillabilite opposees, correspondant a une hydrophobie et a une hydrophilie
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
WO1999024017A1 (fr) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Nouvelle forme posologique par voie orale pour le carvedilol
AU1649700A (en) * 1998-12-22 2000-07-12 Novo Nordisk A/S Novel formulation
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
AU772713B2 (en) 1999-04-01 2004-05-06 Wm. Wrigley Jr. Company Long flavor duration releasing structures for chewing gum
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
JP2004513975A (ja) 2000-12-05 2004-05-13 マクグレゴール　アレキサンダー 作用物質の制御放出のための静水圧デリバリシステム
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
AU2003278407A1 (en) * 2002-10-22 2004-05-13 Ranbaxy Laboratories Limited Sustained release compositions containing alfuzosin
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
BRPI0515825A (pt) 2004-11-02 2008-08-05 Gangagen Life Sciences Inc formulações de bacteriófagos estabilizadas
EP1927358A4 (fr) * 2005-08-23 2010-10-13 Nissan Chemical Ind Ltd Préparation à libération retardée
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
CA2677053C (fr) * 2007-01-31 2016-03-15 Methylation Sciences International Srl Formulations pharmaceutiques a liberation prolongee de s-adenosylmethionine
WO2008102235A1 (fr) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Formulations d'alfuzosine à libération contrôlée
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
KR100836960B1 (ko) * 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
US8445020B2 (en) * 2008-05-19 2013-05-21 Pharmalyte Solutions, Llc High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
WO2016176652A2 (fr) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Cellules souches modifiées et leurs utilisations
EP3364955B1 (fr) 2015-10-09 2022-04-20 RB Health (US) LLC Formulation pharmaceutique
CN115429815B (zh) * 2021-06-02 2023-12-22 广州帝奇医药技术有限公司 一种长效饱腹组合物、制备方法及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
US3590117A (en) * 1969-03-24 1971-06-29 Richardson Merrell Inc Long-lasting troche containing guar gum
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CA945899A (en) * 1971-09-16 1974-04-23 Hans Lowey Long-acting oral carrier
GB1430684A (en) * 1972-06-26 1976-03-31 Lowey H Prolonged release lozenges
US3876771A (en) * 1973-09-04 1975-04-08 Hallister Inc Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS55118414A (en) * 1979-03-05 1980-09-11 Teijin Ltd Prolonged release drug and its preparation
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
CA1146866A (fr) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Procede de production d'un compose pharmaceutique a liberation continue sous forme solide
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS58192817A (ja) * 1982-05-06 1983-11-10 Nippon Soda Co Ltd 棒状製剤の製造方法
CA1208558A (fr) * 1982-10-07 1986-07-29 Kazuo Kigasawa Medicament oral
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DE3443587A1 (de) 1985-06-27
JPS60185728A (ja) 1985-09-21
DK569784A (da) 1985-06-02
MX161165A (es) 1990-08-09
DK569784D0 (da) 1984-11-30
NL193164C (nl) 1999-01-05
FI82601C (fi) 1991-04-10
HUT35531A (en) 1985-07-29
FR2555901B1 (fr) 1988-06-10
AU3449984A (en) 1985-06-06
CH664970A5 (de) 1988-04-15
NO167002B (no) 1991-06-17
ZA849373B (en) 1985-07-31
IT1177152B (it) 1987-08-26
LU85660A1 (de) 1985-06-04
ATA382484A (de) 1992-01-15
EG17134A (en) 1991-08-30
NO844280L (no) 1985-06-03
SE8406081D0 (sv) 1984-11-30
FI82601B (fi) 1990-12-31
DE3443587C2 (de) 1986-11-06
IE58112B1 (en) 1993-07-14
IT8423523A1 (it) 1986-05-09
IT8423523A0 (it) 1984-11-09
IL73594A (en) 1988-12-30
SE461071B (sv) 1990-01-08
NZ210310A (en) 1988-01-08
PT79427B (en) 1986-09-15
US4680323A (en) 1987-07-14
CA1229551A (fr) 1987-11-24
NL193164B (nl) 1998-09-01
HU193717B (en) 1987-11-30
KR930000046B1 (ko) 1993-01-06
AT394948B (de) 1992-07-27
GB2152940A (en) 1985-08-14
DK162511B (da) 1991-11-11
NO167002C (no) 1991-09-25
PT79427A (en) 1984-11-01
IL73594A0 (en) 1985-02-28
IE843077L (en) 1985-06-01
FI844656L (fi) 1985-06-02
DK162511C (da) 1992-03-30
SE8406081L (sv) 1985-06-02
NL8403522A (nl) 1985-07-01
GB8430083D0 (en) 1985-01-09
FI844656A0 (fi) 1984-11-27
GB2152940B (en) 1987-09-03
FR2555901A1 (fr) 1985-06-07
AU572571B2 (en) 1988-05-12
KR850004392A (ko) 1985-07-15

Similar Documents

Publication Publication Date Title
BE901186A (fr) Procede et composition pour la preparation de produits pharmaceutiques a effet retard controle pour l'administration orale.
FR2559389B1 (fr) Procede pour la preparation de compositions pharmaceutiques a liberation soutenue, ayant une forte teneur en ingredient actif
AU4786096A (en) Solid active agent preparations
HUT50631A (en) Process for producing long-acting pharmaceutical compositions comprising etodolac active ingredient
BE899885A (fr) Comprimes de naproxen et de naproxen sodique a liberation controlee.
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
GB1446352A (en) Pharmaceutical compositions
ATE14884T1 (de) S-adenosinylmethionine-derivate, verfahren zu ihrer herstellung und die pharmazeutischen zusammensetzungen welche als aktive substanz diese derivate enthalten.
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
GB1487334A (en) Pharmaceutical preparations comprising lisuride and/or physiologically tolerable salts thereof
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
US3144387A (en) Anti-inflammatory compositions
EP0543855A1 (fr) Utilisation de composes d'aryle hydroxyuree pour le traitement de l'atherosclerose
CA1307739C (fr) Compositions anti-inflammatoires
DE68900152D1 (de) Acetylcystein enthaltendes, festes, wasserloeslisches arzneimittel.
BG94824A (bg) Таблетка, съдържаща натриев 2-меркаптоетансулфонат (месна), като активно вещество и метод за получаването й
ES8308833A1 (es) "un metodo para la preparacion de 3-fenil-1-indanaminas".
US2906665A (en) L-amphetamine alginate
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
GB1497729A (en) Benzenesulphonyl ureas and process for their manufacture
FR2383664A1 (fr) Composition solide contenant un steroide et son procede de preparation
US3636210A (en) Cholanic acid and cholenic acid compositions and method of treatment
GB1381426A (en) Method of treating mammals and composition comprising oligosaccha ride sulphuric acid esters and nonionic surface active agents
US3639597A (en) Pharmaceutical compositions containing cholanic acid conjugates
US4409222A (en) Pinacidil-diuretic preparation for treating hypertension or congestive heart failure

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 093C0175

RE20 Patent expired

Owner name: HANS *LOWEY

Effective date: 20041130